TABLE 3.
Clinical characteristics
| Patients | Age | Duration of response to hormonal Rx (months) | Survival after hormonal Rx (months) | Survival since diagnosis (months) | Sites of metastasis | Response to chemotherapy (date) |
|---|---|---|---|---|---|---|
| #1 | 72 | 19 | 32 | 55 | Brain, liver, lungs, lytic bone, penis | No response to 5-fluorouracil, paclitaxel, doxorubicin, or cyclophosphamide |
| #2 | 61 | 38 | 62 | 120 | Lungs | No treatment |
| #3 | 62 | 53 | 94 | 127 | Base of skull, liver | Ketoconazole/doxorubicin/estramustine/vinblastine (12/98); no response to mitoxantrone, docetaxel |
| #4 | 62 | 11 | 40 | 84 | Bladder, bone, liver, LN | Ketoconazole/doxorubicin (7/98); no response to cyclophosphamide |
| #5 | 77 | 14 | 83 | 84 | Bone | Ketoconazole/doxorubicin/strontium-89 (9/95) |
| #6 | 52 | 64 | 97 | 184 | Adrenal, liver, LN | Ketoconazole/doxorubicin (8/97); estramustine/paclitaxel/etoposide (2/98); cyclophosphamide/vincristine/dexamethasone (2/99); no response to mitoxantrone, estrmustine/vinblastine, docetaxel |
| #7 | 64 | 30 | 51 | 170 | Bladder, lungs, LN | No treatment |
| #8 | 51 | 37 | 60 | 170 | Bladder, bone, liver, LN, lungs | Ketoconazole/doxorubicin/estramustine/vinblastine (11/97); Cyclophosphamide/cisplatin/etoposide (5/98); Cyclophosphamide/doxorubicin/vincristine (3/99); no response to docetaxel, etoposide, carboplatin |
| #9 | 66 | 12 | 18 | 113 | Adrenal, bladder, pancreas | No treatment |
| #10 | 69 | 27 | 47 | 48 | Bone | No response to mitoxantrone, doxorubicin, paclitaxel, vinblastine, etoposide |
| #11 | 64 | 12 | 30 | 75 | Bone, lungs | Ketoconazole/mitoxantrone/Sr-89 (6/98) Did not benefit from cytoxan or taxotere |